PP
CTKB icon

Paloma Partners’s Cytek Biosciences CTKB Stock Holding History

Paloma Partners’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-40,751
Closed -$439K – 1232
2022
Q1 		$439K Buy
40,751
+29,906
+276% +$404K 0.01% 860
2021
Q4 		$177K Sell
10,845
-2,142
-16% -$44.9K ﹤0.01% 1643
2021
Q3 		$278K Buy
+12,987
New +$305K 0.01% 750

Other funds holding CTKB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Paloma Partners's CTKB Position: Q2 2022 in Review

Paloma Partners sold out of Cytek Biosciences (CTKB) in Q2 2022, closing a stake of 40,751 shares — an estimated $439K sold.

Paloma Partners first reported a position in CTKB in Q3 2021 and held it in 3 quarters. The position peaked at $439K in Q1 2022. 84 funds tracked by Wall St. Rank hold CTKB as of Q2 2022.

  • Paloma Partners reported no remaining Cytek Biosciences position as of Q2 2022 after selling out during the quarter.
  • Paloma Partners sold 40,751 Cytek Biosciences shares in Q2 2022, an estimated $439K.
  • Paloma Partners first reported a position in Cytek Biosciences in Q3 2021 and held it in 3 quarters.
  • Paloma Partners's Cytek Biosciences position peaked at $439K in Q1 2022.
  • 84 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2022.

Based on Paloma Partners's 13F filing for Q2 2022, filed 15 Aug 2022.